ANA development following anti-TNF therapy is common.12 According to prospective rheumatoid arthritis cohorts, 31–63% of patients treated with infliximab and 16–51% of patients treated with adalimumab developed ANA.4 In contrast, only few patients develop ATIL. Here, TNF is linked to rheumatoid arthritis.